Princeton, New Jersey, November 10, 2014 – Sandoz today announced the US market introduction of cyclophosphamide injection, USP.

Sandoz is launching cyclophosphamide injection, USP, through collaboration with Jiangsu Hengrui Medicine Co., the owner of the product’s Abbreviated New Drug Application (ANDA).

Cyclophosphamide for injection, USP, is a chemotherapy agent used to treat certain types of cancer in adults and pediatric patients. It is also used in selected cases of biopsy proven “minimal change” nephrotic syndrome in children. New cases of leukemia, …